Cover Image

An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial

Prognosis in advanced pancreatic ductal adenocarcinoma (aPDAC) is particularly poor, only few patients benefit from treatment, and there are few biomarkers. The PREDICT trial examined whether first-line time-to-treatment failure (TTF1) predicts second-line treatment failure (TTF2) in aPDAC patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Lahusen, Anton (Author) , Lutz, Manfred P. (Author) , Fang, Rui (Author) , Kirchner, Martina (Author) , Albus, Sarah (Author) , Kluck, Klaus (Author) , Karthaus, Meinolf (Author) , Schwarzer, Andreas (Author) , Siegler, Gabriele (Author) , Kleger, Alexander (Author) , Ettrich, Thomas J. (Author) , Becher, Alexander (Author) , Höfling, Sabine (Author) , Siveke, Jens T. (Author) , Budczies, Jan (Author) , Tannapfel, Andrea (Author) , Stenzinger, Albrecht (Author) , Cheung, Phyllis Fung-Yi (Author) , Eiseler, Tim (Author) , Seufferlein, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 22 July 2025
In: Molecular cancer
Year: 2025, Volume: 24, Issue: 1, Pages: 1-19
ISSN:1476-4598
DOI:10.1186/s12943-025-02406-7
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12943-025-02406-7
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1186/s12943-025-02406-7?utm_source=getftr&utm_medium=getftr&utm_campaign=getftr_pilot&getft_integrator=clarivate
Get full text
Author Notes:Anton Lahusen, Manfred P. Lutz, Rui Fang, Martina Kirchner, Sarah Albus, Klaus Kluck, Meinolf Karthaus, Andreas Schwarzer, Gabriele Siegler, Alexander Kleger, Thomas J. Ettrich, Alexander Becher, Sabine Höfling, Jens T. Siveke, Jan Budczies, Andrea Tannapfel, Albrecht Stenzinger, Phyllis Fung-Yi Cheung, Tim Eiseler and Thomas Seufferlein
Description
Summary:Prognosis in advanced pancreatic ductal adenocarcinoma (aPDAC) is particularly poor, only few patients benefit from treatment, and there are few biomarkers. The PREDICT trial examined whether first-line time-to-treatment failure (TTF1) predicts second-line treatment failure (TTF2) in aPDAC patients but found no association. We hypothesized that the tumor immune microenvironment (TiME) could correlate with the outcome in this trial and assessed whether tissue features were reflected in peripheral blood.
Item Description:Gesehen am 15.12.2025
Physical Description:Online Resource
ISSN:1476-4598
DOI:10.1186/s12943-025-02406-7

Similar Items